



For people with relapsing MS

It's time for something new.

MS=multiple sclerosis.

Indication

What is KESIMPTA (ofatumumab) injection?

KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease.

It is not known if KESIMPTA is safe or effective in children.

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

Relapsing MS Can Be Overwhelming

It could mean experiencing relapses, worrying about what may come next, and managing the demands of life around treatment schedules. It can all add up.

When it does, it may be time to look into a new relapsing MS treatment, like KESIMPTA®.

Keep reading to:

- › Check out results compared to AUBAGIO®
- › Learn about potential side effects
- › See how a once-a-month injection could fit into your schedule (after 3 weekly starter doses)

AUBAGIO (teriflunomide), a leading oral relapsing MS treatment, is a registered trademark of Sanofi and Genzyme.

Important Safety Information

Who should not take KESIMPTA?

Do NOT take KESIMPTA if you have active hepatitis B virus (HBV) infection.

What is the most important information I should know about KESIMPTA?

KESIMPTA can cause serious side effects such as:

- **Infections.** Serious infections can happen during treatment with KESIMPTA. (cont)

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**®
(ofatumumab) 20 mg
injection

KESIMPTA® (ofatumumab) 20 mg injection Went Head-To-Head

Over 1,800 people with relapsing MS participated in 2 studies that compared KESIMPTA to AUBAGIO®. All of them had experienced a relapse or saw activity on an MRI in the 1–2 years leading up to the studies.

These studies measured the impact KESIMPTA had on the activity you see, and the activity you don't:

1

Relapses

2

Disability progression

3

Lesions

Important Safety Information

If you have an active infection, your healthcare provider (HCP) should delay your treatment with KESIMPTA until your infection is gone. KESIMPTA taken before or after other medicines that weaken the immune system may increase your risk of getting infections. (cont)

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**®
(ofatumumab) 20 mg injection

The Activity You Can See

Relapses Reduced—Up to 59%

Study 1



Study 2



Not only are relapses unpredictable,
but they interrupt your day-to-day.

Imagine fewer relapses.

Important Safety Information

Tell your HCP right away if you have any infections or get any symptoms including painful and frequent urination, nasal congestion, runny nose, sore throat, fever, chills, cough, or body aches. (cont)

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**®
(ofatumumab) 20 mg
injection

The Activity You Can See

Disability Progression— It's Less Likely

Studies 1 & 2 Combined



Knowing disability could get worse is top of mind
for some people with relapsing MS.

What if there were less chance of your disability progressing?

*Based on whether disability progression was still present 3 and 6 months after disability symptoms started.

Important Safety Information

- **HBV reactivation.** If you have ever had HBV infection, it may become active again during or after treatment with KESIMPTA (reactivation). (cont)


Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**®
(ofatumumab) 20 mg
injection


The Activity You Don't See

Less Active Lesions—Way Less

Study 1



Study 2



If these lesions show up, it may mean your relapsing MS is more active than you're aware of.

How would you feel walking into an MRI if you knew there could be less of these lesions?

Gd+=gadolinium-enhancing.

Important Safety Information

If this happens, it may cause serious liver problems including liver failure or death. Before starting KESIMPTA, your HCP will do a blood test to check for HBV. (cont)

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta®**
(ofatumumab) 20 mg injection

The Activity You Don't See

Less New or Enlarging (T2) Lesions—A Lot Less

Study 1



Study 2



These lesions, both old and new, show the impact relapsing MS has on the brain.

What if you could expect significantly less of these lesions?

Important Safety Information

They will also continue to monitor you during and after treatment with KESIMPTA for HBV. Tell your HCP right away if you get worsening tiredness or yellowing of your skin or the white part of your eyes. (cont)

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta[®]**
(ofatumumab) 20 mg injection

Let's Talk Safety

KESIMPTA® works by impacting your immune system, so it could increase the risk of getting serious infections, including:

- **Hepatitis B virus (HBV) reactivation:** Before starting KESIMPTA, you'll get a blood test for HBV. If you've ever had HBV infection, it may become active again during or after treatment with KESIMPTA.
- **Progressive multifocal leukoencephalopathy (PML):** PML may happen with KESIMPTA. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks, and can result in death or severe disability.

Before you take KESIMPTA, tell your doctor if you have any infections. It's also important to tell your doctor if you:

- Have or think you have HBV or PML
- Have taken or plan to take medication that affects your immune system
- Had a recent vaccination or have one scheduled
- Are pregnant, think you may be, or are planning to be
- Are breastfeeding or plan to

Another serious side effect is:

Low immunoglobulins: KESIMPTA may decrease some types of antibodies. Your doctor will do blood tests to check your immunoglobulin levels.

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**®
(ofatumumab) 20 mg
injection

Here's What's Most Common

Injection-related reactions were mostly mild to moderate. They mostly happen with the first injection, although they can happen with later injections.

Local injection-site reactions

Symptoms include redness, pain, itching, and swelling.



Injection-related reactions

Symptoms include fever, headache, muscle pain, chills, and fatigue.



Other possible side effects include:

Upper respiratory infections

Symptoms include sore throat, runny nose, and headache.



Headache



Important Safety Information

- **Progressive Multifocal Leukoencephalopathy (PML).** PML may happen with KESIMPTA. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. (cont)

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**[®]
(ofatumumab) 20 mg
injection

Treat Once a Month With Your Sensoready[®] Pen

Once you're ready to inject, you'll be done in no time

- › KESIMPTA[®] can be taken from the **convenience of your home**
- › **The injection usually takes several seconds**
- › There are **no premedications required***

Someone from your health care team will give guidance on how to take KESIMPTA for the first time.



If you need more support, watch online at **[kesimptaresources.com](https://www.kesimptaresources.com)**

*Only limited benefit of premedication was observed in relapsing MS clinical studies.

Important Safety Information

PML can result in death or severe disability. Tell your HCP right away if you have any new or worsening neurologic signs or symptoms. These may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory, which may lead to confusion and personality changes. (cont)


Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta[®]**
(ofatumumab) 20 mg
injection

Here's Your Treatment Schedule

You'll get to once a month before you know it

You'll give yourself **1 dose per week for the first 3 weeks**, and then you'll **skip a week**. After that, you can move on to **1 dose per month**.



Important Safety Information

- **Weakened immune system.** KESIMPTA taken before or after other medicines that weaken the immune system could increase your risk of getting infections. (cont)

Please see full Important Safety Information throughout this brochure. [Click here for full Prescribing Information including Medication Guide.](#)

 **Kesimpta**[®]
(ofatumumab) 20 mg injection

Now Let's Get You Started

Your prescription comes with an Alongside™ KESIMPTA® membership

Our goal is to keep things simple. We'll help take care of the details while you start treatment, and provide you with support and resources along the way.

Your doctor will get you enrolled. Here's what happens next:

- › **We'll help get you started** by figuring out coverage, savings eligibility (including a **\$0* Access Card**), and delivery
- › **We'll mail you a welcome package** with some important details inside
- › **You'll get a dedicated Coordinator** who will answer any questions throughout your membership

*Limitations apply. People with commercial insurance may receive up to an \$18,000 annual limit and/or up to 12 months of free product while coverage is pursued. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. See complete Terms & Conditions at start.kesimpta.com.

Important Safety Information

Before you take KESIMPTA, tell your HCP about all your medical conditions, including if you:

- Have or think you have an infection including HBV or PML.
- Have ever taken, currently take, or plan to take medicines that affect your immune system. These medicines could increase your risk of getting an infection. (cont)

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**®
(ofatumumab) 20 mg
injection

Your Coordinator Has Your Back

Ask them about:

- › Coverage for treatment
- › Delivery of KESIMPTA
- › Supplemental injection training and resources
- › On-the-go resources
- › Long-term support



We'll call you once you're enrolled,
but you can always reach us here:
**1-855-KESIMPTA (1-855-537-4678),
8:30 AM–8:00 PM ET, Mon–Fri**

Important Safety Information

- Have had a recent vaccination or are scheduled to receive any vaccinations.
 - You should receive any required 'live' or 'live-attenuated' vaccines at least 4 weeks before you start treatment with KESIMPTA. (cont)

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

Alongside™
Kesimpta®
(ofatumumab) 20 mg
injection

Indication

What is KESIMPTA (ofatumumab) injection?

KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease.

It is not known if KESIMPTA is safe or effective in children.

Important Safety Information

Who should not take KESIMPTA?

Do NOT take KESIMPTA if you have active hepatitis B virus (HBV) infection.

What is the most important information I should know about KESIMPTA?

KESIMPTA can cause serious side effects such as:

- **Infections.** Serious infections can happen during treatment with KESIMPTA. If you have an active infection, your healthcare provider (HCP) should delay your treatment with KESIMPTA until your infection is gone. KESIMPTA taken before or after other medicines that weaken the immune system may increase your risk of getting infections. Tell your HCP right away if you have any infections or get any symptoms including painful and frequent urination, nasal congestion, runny nose, sore throat, fever, chills, cough, or body aches.
- **HBV reactivation.** If you have ever had HBV infection, it may become active again during or after treatment with KESIMPTA (reactivation). If this happens, it may cause serious liver problems including liver failure or death. Before starting KESIMPTA, your HCP will do a blood test to check for HBV. They will also continue to monitor you during and after treatment with KESIMPTA for HBV. Tell your HCP right away if you get worsening tiredness or yellowing of your skin or the white part of your eyes.

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**[®]
(ofatumumab) 20 mg
injection

Important Safety Information (cont)

- **Progressive Multifocal Leukoencephalopathy (PML).** PML may happen with KESIMPTA. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your HCP right away if you have any new or worsening neurologic signs or symptoms. These may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory, which may lead to confusion and personality changes.
- **Weakened immune system.** KESIMPTA taken before or after other medicines that weaken the immune system could increase your risk of getting infections.

Before you take KESIMPTA, tell your HCP about all your medical conditions, including if you:

- Have or think you have an infection including HBV or PML.
- Have ever taken, currently take, or plan to take medicines that affect your immune system. These medicines could increase your risk of getting an infection.
- Have had a recent vaccination or are scheduled to receive any vaccinations.
 - You should receive any required 'live' or 'live-attenuated' vaccines at least 4 weeks before you start treatment with KESIMPTA. You should not receive 'live' or 'live-attenuated' vaccines while you are being treated with KESIMPTA and until your HCP tells you that your immune system is no longer weakened.
 - Whenever possible, you should receive any 'non-live' vaccines at least 2 weeks before you start treatment with KESIMPTA.
 - Talk to your HCP about vaccinations for your baby if you used KESIMPTA during your pregnancy.
- Are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if KESIMPTA will harm your unborn baby. Females who can become pregnant should use birth control (contraception) during treatment with KESIMPTA and for 6 months after

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**[®]
(ofatumumab) 20 mg
injection

Important Safety Information (cont)

your last treatment. Talk with your HCP about what birth control method is right for you during this time.

- Are breastfeeding or plan to breastfeed. It is not known if KESIMPTA passes into your breast milk. Talk to your HCP about the best way to feed your baby if you take KESIMPTA.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I use KESIMPTA?

See the detailed Instructions for Use that comes with KESIMPTA for information about how to prepare and inject a dose of KESIMPTA and how to properly throw away (dispose of) used KESIMPTA Sensoready pens or prefilled syringes.

- Use KESIMPTA exactly as your HCP tells you to use it.
- Your HCP will show you how to prepare and inject KESIMPTA the right way before you use it for the first time.
- **Do not** inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with moles, scars, or stretch marks.

KESIMPTA may cause serious side effects including:

- **Injection-related reactions.** Injection-related reactions are a common side effect of KESIMPTA. Injecting KESIMPTA can cause injection-related reactions that can happen within 24 hours (1 day) following the first injections and with later injections. Talk with your HCP if you have any of these signs and symptoms:
 - **at or near the injection site:** redness of the skin, swelling, itching, and pain or
 - **that may happen when certain substances are released in your body:** fever, headache, pain in the muscles, chills, and tiredness.
- **Low immunoglobulins.** KESIMPTA may cause a decrease in some types of antibodies. Your HCP will do blood tests to check your blood immunoglobulin levels.

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**[®]
(ofatumumab) 20 mg
injection

Important Safety Information (cont)

The most common side effects of KESIMPTA include:

- Upper respiratory tract infection, with symptoms such as sore throat and runny nose, and headache.
- Headache.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information including Medication Guide on www.Kesimpta.com.

 **Kesimpta**[®]
(ofatumumab) 20 mg
injection

What's Important to You About Treatment?

Consider what KESIMPTA® can offer for your relapsing MS

- › It impacts the **disease activity** you see and the activity you don't
- › It's a **once-a-month** injection you can take from home
- › The injection usually takes **several seconds**

There's more online:



KESIMPTA.com



KESIMPTA (ofatumumab)



@kesimpta_ofatumumab

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**[®]
(ofatumumab) 20 mg injection

KESIMPTA, the KESIMPTA logo, and SENSOREADY are registered trademarks of Novartis AG. ALONGSIDE and the ALONGSIDE logo are trademarks of Novartis AG.

